UFP Technologies Inc
XMUN:UFP

Watchlist Manager
UFP Technologies Inc Logo
UFP Technologies Inc
XMUN:UFP
Watchlist
Price: 194.34 EUR 1% Market Closed
Market Cap: €1.5B

UFP Technologies Inc
Investor Relations

UFP Technologies makes custom-engineered packaging, protective packaging, and component parts from foam, plastic, and other specialty materials. It does not sell a single standard product line; instead, it works with customers to design and manufacture parts that fit specific shapes, performance needs, and handling requirements. Its products are used to protect, organize, cushion, or support items during use, shipping, and assembly. The company serves customers in medical devices, healthcare, industrial markets, and some consumer applications. A large part of its business comes from medical customers that need clean, precise, and often single-use components for devices, trays, and packaging. UFP Technologies makes money by designing these custom parts and then selling the finished goods it manufactures, often as an ongoing supplier tied to a customer’s product program. What makes its business model different is the custom, engineering-heavy role it plays in the supply chain. Customers often rely on UFP Technologies to turn a design idea into a manufacturable part and then produce it consistently over time. That makes the company less like a commodity materials seller and more like a specialized manufacturing partner embedded in its customers’ product development and production process.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
May 5, 2026
AI Summary
Q1 2026

Revenue: First-quarter revenue grew 4.1%, helped by 5.9% medical sales growth, while nonmedical sales fell 15% as the company continued shifting toward faster-growing MedTech categories.

Margins: Gross margin improved to 28.8% from 28.5%, and adjusted operating margin was 16.7%, despite startup costs, AJR labor inefficiencies, and legal expenses.

New Programs: Four major program launches are ramping slowly now, but management said three of the four customers have already asked to double capacity, with stronger contribution expected in the second half.

Customer Mix: Growth in robotic surgery, patient surfaces and support, and interventional and surgical offset weakness in wound care, where two major customers temporarily slowed because of excess inventory.

Capacity Expansion: The company is adding buildings in Santiago and La Romana in the Dominican Republic and is also planning added capacity in APAC to support demand.

Outlook: Management sounded upbeat on the year ahead, saying new program revenue should accelerate in Q2 and become more meaningful in Q3 and Q4, while acquisition activity remains active but disciplined.

Key Financials
Revenue
4.1% growth
Medical sales growth
5.9% growth
Nonmedical sales growth
15% decline
Robotic surgery growth
7% growth
Patient surfaces and support growth
11% growth
Interventional and surgical growth
15% growth
Gross margin
28.8%
Adjusted operating margin
16.7%
Adjusted earnings per diluted share
$2.48
Cash from operations
$3.2 million
Capital expenditures
$1.7 million
Debt paid down after quarter-end
$4 million
Leverage ratio
approximately 1.14x
SG&A expense
$21 million
Back-office investment expense
approximately $750,000
Noncash equity compensation
approximately $0.5 million
Nonrecurring legal expenses
approximately $0.5 million
Sales pushed into Q2
approximately $1 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. R. Jeffrey Bailly CPA
CEO & Chairman
No Bio Available
Mr. Mitchell Caplan Rock
President
No Bio Available
Mr. Ronald J. Lataille
CFO, Senior VP & Treasurer
No Bio Available
Mr. Jason Holt
VP & Chief Commercial Officer
No Bio Available
Mr. Steven G. Cardin
VP & COO of MedTech
No Bio Available
Ms. Daniella Mehalik
Vice President of Finance
No Bio Available

Contacts

Address
MASSACHUSETTS
Newburyport
100 Hale Street
Contacts
+19783522200.0
www.ufpt.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett